Category: Assay Development and Screening

1219-E - The Advent of Array SPR for the Rapid Generation of Kinetic Screening Data from up to 384 Samples in Parallel

Wednesday, February 7, 2018
11:30 AM - 12:30 PM

Throughput, speed, resolution, and sample consumption are typically key limiting factors for detailed kinetic characterization early in monoclonal antibody (mAb) discovery campaigns. Here, we show that Array SPR can facilitate the generation of high quality kinetic data from a large panel of clones rapidly and with minimal sample consumption. In this example of a single day’s run, 384 independent kinetic measurements were made on an array comprised of 43 unique mAbs, each immobilized at 8-16 capacities, using a capture approach which does not require purified material. This method required less than 1 μg per mAb and only 2 μg of the recombinant monomeric antigen. The array format provided well-described and highly reproducible kinetic measurements for clones spanning a 10,000-fold affinity range for their target antigen. These data clearly demonstrate the efficiency and quality of kinetic analysis that is possible using Array SPR.

Yasmina Abdiche

Chief Scientific Officer
Carterra
Salt Lake City, UT

Yasmina Noubia Abdiche, PhD, Chief Scientific Officer (CSO), Carterra
Dr. Abdiche joined Carterra as CSO in 2016 after twelve and half years’ experience in the pharmaceutical industry at Rinat-Pfizer, where she was a Research Fellow, a member of Rinat’s leadership team, served on the governing committee for Pfizer’s Postdoctoral Program, and led a group of analytical scientists that applied label-free biosensors to the discovery of therapeutic antibodies. After graduating from Oxford University in the UK with a PhD in Biological Chemistry and a Master’s degree in Chemistry, Dr. Abdiche completed postdoctoral research in Dr. David Myszka’s laboratory at the University of Utah in Salt Lake City, where she optimized biosensor methods for characterizing small molecule interactions. Dr. Abdiche is co-inventor of several therapeutic antibodies in clinical trials, including Teva’s fremanezumab (formerly TEV-48125, RN-307) an anti-CGRP antibody which successfully completed PhIII clinical trials for chronic migraine and is expected to achieve US market approval in 2018, bococizumab, a PCSK9 inhibitor that was tested in PhIII clinical trials for hypercholesteremia, and RN888, a PD-1 inhibitor currently in PhI clinical trials for cancer immunotherapy.